- Home
- OXLC vs JANX Comparison
OXLC vs JANX Comparison
Compare OXLC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXLC
- JANX
- Stock Information
- Founded
- OXLC 2010
- JANX 2017
- Country
- OXLC United States
- JANX United States
- Employees
- OXLC N/A
- JANX N/A
- Industry
- OXLC Investment Managers
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- OXLC Finance
- JANX Health Care
- Exchange
- OXLC Nasdaq
- JANX Nasdaq
- Market Cap
- OXLC 1.7B
- JANX 1.5B
- IPO Year
- OXLC N/A
- JANX 2021
- Fundamental
- Price
- OXLC $3.57
- JANX $24.30
- Analyst Decision
- OXLC Strong Buy
- JANX Strong Buy
- Analyst Count
- OXLC 1
- JANX 8
- Target Price
- OXLC $6.00
- JANX $86.63
- AVG Volume (30 Days)
- OXLC 1.9M
- JANX 892.5K
- Earning Date
- OXLC 11-01-2023
- JANX 08-07-2025
- Dividend Yield
- OXLC 18.86%
- JANX N/A
- EPS Growth
- OXLC N/A
- JANX N/A
- EPS
- OXLC 1.20
- JANX N/A
- Revenue
- OXLC $130,145,365.00
- JANX $439,000.00
- Revenue This Year
- OXLC $136.15
- JANX N/A
- Revenue Next Year
- OXLC $5.51
- JANX $591.60
- P/E Ratio
- OXLC $4.24
- JANX N/A
- Revenue Growth
- OXLC N/A
- JANX N/A
- 52 Week Low
- OXLC $4.41
- JANX $21.97
- 52 Week High
- OXLC $5.70
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- OXLC 48.25
- JANX 47.89
- Support Level
- OXLC $3.18
- JANX $23.30
- Resistance Level
- OXLC $3.45
- JANX $26.13
- Average True Range (ATR)
- OXLC 0.09
- JANX 1.53
- MACD
- OXLC 0.04
- JANX 0.04
- Stochastic Oscillator
- OXLC 95.12
- JANX 51.42
About OXLC Oxford Lane Capital Corp.
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.